Clinical studies on effects of chemotherapy treatment combined with adoptive immunotherapy in patients of advanced digestive malignant tumor

Objective:To evaluate the clinical anti-cancer efficacy of DC activated and Cytokine induced Killer Cells(DCIK) combined with chemotherapy in treating patients of advanced digestive malignant tumor(DMT).Methods:Twenty three patients diagnosed as advanced DMT in General Hospital of Chinese Armed Police Forces from 2005 to 2007 were treated by DCIK combined with systemic chemotherapy as combination therapy group,20 advanced DMT patients at the same time were treated by chemotherapy only as control group.Peripheral blood mononuclear cells(PBMC) were isolated from patients of combination therapy group before chemotherapy.PBMC were induced to DCIK cells in vitro.The qualified DCIK cells were administered to the patients of combination group after 2 periods of systemic chemotherapy.The patients of chemotherapy group were treated with 2 periods of systemic chemotherapy only.Short-term effect,the improvement degree of clinical benefit response,serum tumor markers,immunological indexes and 1-year,3-year survival rate were observed.Results:The short-term effect of 2 groups was of no significant difference(P 0.05).KPS score of combination therapy group was increased(P0.05) after treatment than that of before,while KPS score of chemotherapy group showed no improvement(P0.05)after treatment.The peripheral blood CD3+CD8+,CD3+ CD56+ cells of combination therapy group were significantly increased(P0.01) after treatment than that of before,while the CD3+CD8+,CD3+CD56+ cells of chemotherapy group were no significant change(P 0.05).1-year survival rate of combined therapy group was 78.3%;1-year survival rate of chemotherapy group was 80%(P 0.05).3-year survival rate of combination therapy group was 52.2%;3-year survival rate of chemotherapy group was 30%(P0.01).Conclusion:DCIK combined with chemotherapy have better clinical anti-cancer efficacy,quality of life,immune function and 3-year survival rate in treatment of advanced digestive malignant tumor.